Back to top
more

Cassava Sciences (SAVA)

(Delayed Data from NSDQ)

$2.32 USD

2.32
877,420

+0.07 (3.11%)

Updated Aug 12, 2025 04:00 PM ET

After-Market: $2.32 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (85 out of 245)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Biogen's (BIIB) Aducanumab Gets CHMP's Negative Trend Vote

by Zacks Equity Research

Biogen's (BIIB) regulatory application seeking approval for its Alzheimer's drug, Aduhelm, in Europe hits setback as it receives negative trend vote from the CHMP.

Zacks Equity Research

Cassava (SAVA) Down on Report of SEC Investigation Into AD Program

by Zacks Equity Research

Cassava (SAVA) tanks on reports of an investigation by the SEC related to data reports on its AD candidate.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Regeneron, Moderna, Cassava Sciences, Biohaven Pharma and Pfizer

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Regeneron, Moderna, Cassava Sciences, Biohaven Pharma and Pfizer

Zacks Equity Research

Biotech Stock Roundup: REGN, MRNA Post Q3 Earnings, SAVA Gains on AD Review Data

by Zacks Equity Research

Earnings and other updates from bigwigs like Regeneron (REGN) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.

Zacks Equity Research

Cassava Sciences (SAVA) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Investors will watch for updates on its lead candidate, sumifilam, for Alzheimer's disease in Cassava's (SAVA) Q3 earnings call.

Zacks Equity Research

Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Cassava Sciences, Inc. (SAVA) closed at $44.46 in the latest trading session, marking a -0.34% move from the prior day.

Zacks Equity Research

Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Cassava Sciences, Inc. (SAVA) closed at $47.17 in the latest trading session, marking a -1.34% move from the prior day.

Zacks Equity Research

Cassava Sciences, Inc. (SAVA) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Cassava Sciences, Inc. (SAVA) closed at $50.16 in the latest trading session, marking a +0.95% move from the prior day.

Zacks Equity Research

Roche's (RHHBY) AD Drug Gets Breakthrough Therapy Status

by Zacks Equity Research

Roche (RHHBY) gets Breakthrough Therapy Designation for gantenerumab for Alzheime's disease, which puts the spotlight on this challenging but promising space.

Zacks Equity Research

Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $51.08, marking a -0.8% move from the previous day.

Zacks Equity Research

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH

Zacks Equity Research

Cassava (SAVA) Begins First Efficacy Study on Simufilam in AD

by Zacks Equity Research

Cassava (SAVA) starts a phase III efficacy study evaluating simufilam for treating patients with Alzheimer's disease.

Zacks Equity Research

Cassava Sciences, Inc. (SAVA) Stock Moves -0.1%: What You Should Know

by Zacks Equity Research

Cassava Sciences, Inc. (SAVA) closed at $62.08 in the latest trading session, marking a -0.1% move from the prior day.

Zacks Equity Research

Biogen (BIIB) Seeks Approval for Another Alzheimer's Candidate

by Zacks Equity Research

Biogen (BIIB) and partner Eisai start rolling submission of a regulatory filing seeking approval for lecanemab (BAN2401) as a potential approval for early Alzheimer's disease.

Zacks Equity Research

Cassava (SAVA) Posts Top-Line Data from AD Study on Simufilam

by Zacks Equity Research

Cassava (SAVA) reports top-line data from an interim analysis of the on-going study evaluating simufilam in patients with mild-to-moderate Alzheimer's disease.

Zacks Equity Research

Cassava Sciences, Inc. (SAVA) Stock Moves -0.52%: What You Should Know

by Zacks Equity Research

Cassava Sciences, Inc. (SAVA) closed at $48.26 in the latest trading session, marking a -0.52% move from the prior day.

Zacks Equity Research

Cassava Sciences, Inc. (SAVA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $43.95, marking a +0.07% move from the previous day.

Zacks Equity Research

Do Options Traders Know Something About Cassava Sciences (SAVA) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.

Zacks Equity Research

Biogen (BIIB) Alzheimer's Drug Aduhelm Sees Slow Launch, Stock Down

by Zacks Equity Research

Biogen's (BIIB) new Alzheimer's drug, Aduhelm, can bring in huge revenues, if successfully commercialized.

Zacks Equity Research

Biotech Stock Roundup: REGN Gives Study Update, INCY Wins Drug Approval & More

by Zacks Equity Research

Regulatory and pipeline updates from Regeneron (REGN) and Incyte (INCY), among others, have been in focus in the biotech industry over the past week.

Zacks Equity Research

Cassava (SAVA) Down as Quanterix Issues Statement on AD Study

by Zacks Equity Research

Cassava (SAVA) tanks yet again after Quanterix stated that it did not interpret the test results or prepare the data charts presented by the former.

Zacks Equity Research

Cassava (SAVA) Responds to Charges Against its Integrity in AD Study

by Zacks Equity Research

Cassava (SAVA) plunges following charges against its scientific integrity in developing a drug for Alzheimer's disease. The company responds to the same.

Zacks Equity Research

Cassava Sciences (SAVA) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Investors will be keen on updates from on its lead candidate, sumifilam, for Alzheimer's disease when Cassava (SAVA) reports Q2 results.

Zacks Equity Research

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH

Zacks Equity Research

Biotech Stock Roundup: BIIB's AD Drug Update, CVAC's Decline on Vaccine Data & More

by Zacks Equity Research

The biotech sector was in focus last week with pipeline updates from Biogen (BIIB) and CureVac (CVAC), among others.